Leslie Leinwand - MyoKardia Co-Founder

Founder

Leslie Leinwand is Co-Founder of MyoKardia
Phone650 741-0900
Webwww.myokardia.com

MyoKardia Management Efficiency

The company has return on total asset (ROA) of (23.07) % which means that it has lost $23.07 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (42.7) %, meaning that it created substantial loss on money invested by shareholders. MyoKardia's management efficiency ratios could be used to measure how well MyoKardia manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 51.61 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. MyoKardia has a current ratio of 17.62, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist MyoKardia until it has trouble settling it off, either with new capital or with free cash flow. So, MyoKardia's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like MyoKardia sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for MyoKardia to invest in growth at high rates of return. When we think about MyoKardia's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 1 records

FOUNDER Age

Pr MDBioNTech SE
59
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. As of November 16, 2020, MyoKardia, Inc. operates as a subsidiary of Bristol-Myers Squibb Company. MyoKardia operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 318 people. MyoKardia (MYOK) is traded on NASDAQ Exchange in USA and employs 318 people.

Management Performance

MyoKardia Leadership Team

Elected by the shareholders, the MyoKardia's board of directors comprises two types of representatives: MyoKardia inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MyoKardia. The board's role is to monitor MyoKardia's management team and ensure that shareholders' interests are well served. MyoKardia's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MyoKardia's outside directors are responsible for providing unbiased perspectives on the board's policies.
Eric Topol, Independent Director
Sunil Agarwal, Independent Director
Christine MD, Co-Founder
Taylor Harris, CFO
Mark Perry, Independent Director
June Lee, COO
Cynthia Ladd, General Counsel
William Fairey, Executive Vice President and Chief Commercial Officer
Wendy Yarno, Independent Director
Kevin Starr, Director
Jake Bauer, Vice President - Business Development and Business Operations
Joseph Lambing, Senior Vice President - Nonclinical and Pharmaceutical Development
Steven Chan, Vice President Corporate Controller
Mary Cranston, Director
Katherine Bowdish, Director
Robert McDowell, Sr. VP of Drug Discovery
David Meeker, Independent Director
Marc Semigran, Chief Medical Officer
Leslie Leinwand, Co-Founder
Tassos Gianakakos, CEO and President and Director
Charles Homcy, Director
Jonathan Fox, Chief Medical Officer
Kimberly Popovits, Independent Director

MyoKardia Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MyoKardia a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons.
You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.

Other Consideration for investing in MyoKardia Stock

If you are still planning to invest in MyoKardia check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MyoKardia's history and understand the potential risks before investing.
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Stocks Directory
Find actively traded stocks across global markets